Blockchain Registration Transaction Record

Aclarion Grants Stock Option to New Commercial Director as Nociscan Demand Soars

Aclarion grants inducement stock option to new Commercial Director Daniel Keefe amid triple-digit growth in Nociscan utilization. Learn how Nociscan uses AI and biomarkers to identify chronic low back pain sources.

This news matters because chronic low back pain affects millions, and Aclarion's Nociscan platform offers a noninvasive, AI-driven solution to pinpoint pain sources, potentially improving treatment success rates. The company's commercial expansion signals growing market adoption, which could lead to better outcomes for patients and reduced healthcare costs. Investors should note the company's strategic hiring and utilization growth as indicators of future performance.